{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:21:14Z","timestamp":1793146874701,"version":"4.5.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["82DZL009B1"],"award-info":[{"award-number":["82DZL009B1"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG; STA 1685-1\/1"],"award-info":[{"award-number":["DFG; STA 1685-1\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017268","name":"Berlin Institute of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Introduction:<\/jats:bold>\n                    The CFTR modulator drug elexacaftor\/tezacaftor\/ivacaftor (ETI) was shown to improve CFTR function and clinical symptoms in patients with cystic fibrosis (CF) with at least one\n                    <jats:italic>F508del<\/jats:italic>\n                    allele. Recently, some case reports suggested potential side effects of ETI on mental health with an increase in depressive symptoms and even suicide attempts in patients with CF. However, the general effects of this triple combination therapy on the mental health status of patients with CF remain largely unknown.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    We, therefore, performed a prospective, observational study in a real-life setting and investigated the relationship between initiation of ETI therapy and changes in mental health in adult patients with CF. We assessed Cystic Fibrosis Questionnaire-Revised (CFQ-R), Patient Health Questionnaire-9 (PHQ-9), Beck\u2019s Depression Inventory \u2013 Fast Screen (BDI-FS) and Generalized Anxiety Disorder 7-item Scale (GAD-7) at baseline and 8\u201316\u00a0weeks after initiation of ETI.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    In total, 70 adult patients with CF with at least one\n                    <jats:italic>F508del<\/jats:italic>\n                    allele and a median age of 27.9\u00a0years were recruited. After initiation of ETI, the CFQ-R respiratory domain score improved by 27.9 (IQR 5.6 to 47.2;\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.001). The PHQ-9 score of depressive symptoms decreased by 1.0 (IQR -3.0 to 0.3;\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.05) with an increase of 16.9% in the group with a minimal score after initiation of ETI and a decrease in the groups of mild (\u221211.3%) or moderate (\u22125.7%) scores compared to baseline. The BDI-FS score of depressive symptoms decreased from 1.0 (IQR 0.0\u20132.0) at baseline to 0.0 (IQR 0.0 to 2.0;\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.05) after initiation of ETI. The group with a minimal BDI-FS score increased by 8.0% after initiation of ETI, whereas the groups with mild (\u22124.9%), moderate (\u22121.6%) or severe (\u22121.6%) scores decreased compared to baseline. The GAD-7 score of anxiety symptoms did not change after initiation of ETI compared to baseline (0.0; IQR -2.0. to 0.0;\n                    <jats:italic>p<\/jats:italic>\n                    = 0.112).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Initiation of ETI improves symptoms of depression in adult patients with CF with at least one\n                    <jats:italic>F508del<\/jats:italic>\n                    allele. However, symptoms of anxiety do not change after short-term therapy with ETI.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2023.1179208","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:41:01Z","timestamp":1682037661000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":53,"title":["Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on mental health of patients with cystic fibrosis"],"prefix":"10.3389","volume":"14","author":[{"given":"Linus","family":"Piehler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Thalemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Thee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jobst","family":"R\u00f6hmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zulfiya","family":"Syunyaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus A.","family":"Mall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Y.","family":"Graeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.01.015","article-title":"Suicide attempts in adolescents with cystic fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor therapy","author":"Arslan","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"B2","doi-asserted-by":"publisher","first-page":"6114","DOI":"10.3390\/ijerph19106114","article-title":"Evaluating the effect of kaftrio on perspectives of health and wellbeing in individuals with cystic fibrosis","volume":"19","author":"Aspinall","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B3","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: A global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jcf.2011.06.012","article-title":"Anxiety and depression in adolescents with CF and their caregivers","volume":"10","author":"Besier","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"B6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jcf.2020.07.002","article-title":"Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis","volume":"20","author":"DiMango","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"B8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jcf.2022.08.018","article-title":"Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor\/tezacaftor\/ivacaftor","volume":"22","author":"Fajac","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"B9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/1471-2466-14-205","article-title":"Symptoms of depression impact the course of lung function in adolescents and adults with cystic fibrosis","volume":"14","author":"Fidika","year":"2014","journal-title":"BMC Pulm. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s10880-021-09825-w","article-title":"Assessing psychosocial distress in cystic fibrosis: Validation of the 'distress in cystic fibrosis Scale","volume":"29","author":"Finlay","year":"2022","journal-title":"J. Clin. Psychol. Med. Settings"},{"key":"B11","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1378\/chest.09-2940","article-title":"Prevalence of symptoms of anxiety and depression in German patients with cystic fibrosis","volume":"138","author":"Goldbeck","year":"2010","journal-title":"Chest"},{"key":"B12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1164\/rccm.202201-0219OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles","volume":"206","author":"Graeber","year":"","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles","volume":"205","author":"Graeber","year":"","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"106147","DOI":"10.1016\/j.rmed.2020.106147","article-title":"Rates of depression and anxiety in Italian patients with cystic fibrosis and parent caregivers: Implementation of the Mental Health Guidelines","volume":"172","author":"Graziano","year":"2020","journal-title":"Respir. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1089\/jwh.2014.4985","article-title":"Gender differences in outcomes of patients with cystic fibrosis","volume":"23","author":"Harness-Brumley","year":"2014","journal-title":"J. Womens Health (Larchmt)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jcf.2021.10.002","article-title":"Mental status changes during elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"21","author":"Heo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B19","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jad.2013.11.024","article-title":"Reliability and validity of the Beck Depression Inventory-Fast Screen for medical patients in the general German population","volume":"156","author":"Kliem","year":"2014","journal-title":"J. Affect Disord."},{"key":"B20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: Validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J. Gen. Intern Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2374373521996971","DOI":"10.1177\/2374373521996971","article-title":"Lingering identity as chronically ill and the unanticipated effects of life-changing precision medicine in cystic fibrosis: A case report","volume":"8","author":"Ladores","year":"2021","journal-title":"J. Patient Exp."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","article-title":"Cystic fibrosis: Emergence of highly effective targeted Therapeutics and potential clinical implications","volume":"201","author":"Mall","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.genhosppsych.2005.07.003","article-title":"Validity of the brief patient health questionnaire mood Scale (PHQ-9) in the general population","volume":"28","author":"Martin","year":"2006","journal-title":"Gen. Hosp. Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","first-page":"100829","DOI":"10.1016\/j.resmer.2021.100829","article-title":"Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease","volume":"80","author":"Martin","year":"2021","journal-title":"Respir. Med. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.mcna.2022.07.005","article-title":"Cystic fibrosis: Highly effective targeted Therapeutics and the impact on sex and racial disparities","volume":"106","author":"Montemayor","year":"2022","journal-title":"Med. Clin. North Am."},{"key":"B27","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.jcf.2021.05.012","article-title":"Sex differences in treatment patterns in cystic fibrosis pulmonary exacerbations","volume":"20","author":"Montemayor","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"B28","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: A clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1177\/1060028013514846","article-title":"Prevalence of depression and antidepressant therapy use in a pediatric cystic fibrosis population","volume":"48","author":"Ploessl","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.ejpain.2008.09.017","article-title":"The utility of the Beck depression inventory Fast screen (BDI-FS) in a pain clinic population","volume":"13","author":"Poole","year":"2009","journal-title":"Eur. J. Pain"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1378\/chest.128.4.2347","article-title":"Development and validation of the cystic fibrosis questionnaire in the United States: A health-related quality-of-life measure for cystic fibrosis","volume":"128","author":"Quittner","year":"2005","journal-title":"Chest"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1136\/thoraxjnl-2014-205983","article-title":"Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: Results of the international depression epidemiological study across nine countries","volume":"69","author":"Quittner","year":"2014","journal-title":"Thorax"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s11136-011-0036-z","article-title":"Psychometric evaluation of the cystic fibrosis questionnaire-revised in a national sample","volume":"21","author":"Quittner","year":"2012","journal-title":"Qual. Life Res."},{"key":"B34","volume-title":"R: A language and environment for statistical computing","year":"2018"},{"key":"B35","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1378\/chest.06-2474","article-title":"The association between depression, lung function, and health-related quality of life among adults with cystic fibrosis","volume":"132","author":"Riekert","year":"2007","journal-title":"Chest"},{"key":"B36","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/ppul.26260","article-title":"A survey assessing the impact of COVID-19 and elexacaftor\/tezacaftor\/ifavacaftor on both physical and mental health in adults with cystic fibrosis","volume":"58","author":"Sakon","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12992-020-00589-w","article-title":"Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: A systematic review and meta-analysis","volume":"16","author":"Salari","year":"2020","journal-title":"Glob. Health"},{"key":"B38","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jcf.2020.07.020","article-title":"Decreased survival in cystic fibrosis patients with a positive screen for depression","volume":"20","author":"Schechter","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"B39","doi-asserted-by":"publisher","first-page":"00127-2017","DOI":"10.1183\/23120541.00127-2017","article-title":"The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites","volume":"4","author":"Schneider","year":"2018","journal-title":"ERJ Open Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/ppul.21238","article-title":"Depressive symptoms in children with cystic fibrosis and parents and its effects on adherence to airway clearance","volume":"45","author":"Smith","year":"2010","journal-title":"Pediatr. Pulmonol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.chest.2022.08.2240","article-title":"Sex and gender in lung diseases and sleep disorders: A state-of-the-art review: Part 2","volume":"163","author":"Sodhi","year":"2023","journal-title":"Chest"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: The GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch. Intern Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of Elexacaftor\/Tezacaftor\/Ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B44","first-page":"1","article-title":"Symptoms of generalized anxiety disorder among adults: United States, 2019","volume":"22","author":"Terlizzi","year":"2020","journal-title":"NCHS Data Brief."},{"key":"B45","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.psym.2020.06.021","article-title":"Trikafta and psychopathology in cystic fibrosis: A case report","volume":"61","author":"Tindell","year":"2020","journal-title":"Psychosomatics"},{"key":"B46","doi-asserted-by":"publisher","first-page":"550","DOI":"10.4187\/respcare.01328","article-title":"Relationship between anxiety, depression, and quality of life in adult patients with cystic fibrosis","volume":"57","author":"Yohannes","year":"2012","journal-title":"Respir. Care"},{"key":"B47","doi-asserted-by":"publisher","first-page":"17534666221144211","DOI":"10.1177\/17534666221144211","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on depression and anxiety in cystic fibrosis","volume":"16","author":"Zhang","year":"2022","journal-title":"Ther. Adv. Respir. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1179208\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:41:05Z","timestamp":1682037665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1179208\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":47,"alternative-id":["10.3389\/fphar.2023.1179208"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1179208","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"article-number":"1179208"}}